Yihan Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yihan Hu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Fang Fang
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
5 shared publications Caroline Ingre
Department of Clinical Neuroscience Karolinska Institutet Stockholm Sweden
4 shared publicationsFredrik Piehl
Department of Clinical Neuroscience Karolinska Institutet Stockholm Sweden
4 shared publicationsChristina Seitz
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
3 shared publicationsFang Fang
Institute of Environmental Medicine Karolinska Institutet Stockholm Sweden
3 shared publications- Huan Song
Sichuan University
3 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (1) , e218072
Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases
The prevalence of Parkinson disease (PD), multiple sclerosis (MS), and motor neuron diseases (MNDs) is rising globally. However, it is unclear to what degree this is related to an increase in incidence or to improved survival after diagnosis. We performed 2 nationwide, population-based, retrospective cohort studies, including all individuals living in Sweden between 2001 and 2016 and living in France between 2009 and 2022, respectively. Pooled mixed-effects regression models, with country as a random effect, were used to determine temporal trends in prevalence, crude and age-standardized and sex-standardized incidence, and age and life expectancy at diagnosis. Annualized prevalence of PD, MS, and MNDs increased significantly between 2003 and 2022 in the pooled model (PD: prevalence ratio [PR] per year = 1.014, p < 0.001; MS: PR = 1.029, p < 0.001; MND: PR = 1.028, p < 0.001). While the crude incidence of both PD and MS remained nearly stable over time (PD: incidence rate ratio [IRR] per year = 0.998, p < 0.001; MS: IRR = 0.992, p < 0.001), the standardized incidence showed a more marked decrease for PD (IRR = 0.986, p < 0.001) while remaining almost unchanged for MS (IRR = 0.995, p < 0.001). For MNDs, both the crude and standardized incidence increased over time (crude IRR = 1.018, p < 0.001; standardized IRR = 1.008, p < 0.001). Life expectancy at diagnosis of PD increased between 2003 and 2013 (+0.95 months per calendar year, p < 0.001) and then decreased between 2013 and 2022 (−1.20 months, p = 0.002), while it increased significantly over the entire study period for MS (+2.35 months, p < 0.001) and MNDs (+0.34 months, p = 0.01). These findings indicate that the rising MS prevalence is largely survival-driven and the rising MND prevalence reflects a true increase in incidence, whereas PD prevalence grows modestly, largely independent of incidence. Depending on the mechanism that drives prevalence, whether increased incidence reflecting changing risk factor exposures, improved survival due to therapeutic advances, or demographic aging of the population, inferences about underlying causes differ substantially between PD, MS, and MNDs, with direct implications for health care planning and etiologic research.
- 14 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (1) , e218072
Open AccessDrivers of Rising Prevalence in Major Motor Neurodegenerative Diseases
The prevalence of Parkinson disease (PD), multiple sclerosis (MS), and motor neuron diseases (MNDs) is rising globally. However, it is unclear to what degree this is related to an increase in incidence or to improved survival after diagnosis. We performed 2 nationwide, population-based, retrospective cohort studies, including all individuals living in Sweden between 2001 and 2016 and living in France between 2009 and 2022, respectively. Pooled mixed-effects regression models, with country as a random effect, were used to determine temporal trends in prevalence, crude and age-standardized and sex-standardized incidence, and age and life expectancy at diagnosis. Annualized prevalence of PD, MS, and MNDs increased significantly between 2003 and 2022 in the pooled model (PD: prevalence ratio [PR] per year = 1.014, p < 0.001; MS: PR = 1.029, p < 0.001; MND: PR = 1.028, p < 0.001). While the crude incidence of both PD and MS remained nearly stable over time (PD: incidence rate ratio [IRR] per year = 0.998, p < 0.001; MS: IRR = 0.992, p < 0.001), the standardized incidence showed a more marked decrease for PD (IRR = 0.986, p < 0.001) while remaining almost unchanged for MS (IRR = 0.995, p < 0.001). For MNDs, both the crude and standardized incidence increased over time (crude IRR = 1.018, p < 0.001; standardized IRR = 1.008, p < 0.001). Life expectancy at diagnosis of PD increased between 2003 and 2013 (+0.95 months per calendar year, p < 0.001) and then decreased between 2013 and 2022 (−1.20 months, p = 0.002), while it increased significantly over the entire study period for MS (+2.35 months, p < 0.001) and MNDs (+0.34 months, p = 0.01). These findings indicate that the rising MS prevalence is largely survival-driven and the rising MND prevalence reflects a true increase in incidence, whereas PD prevalence grows modestly, largely independent of incidence. Depending on the mechanism that drives prevalence, whether increased incidence reflecting changing risk factor exposures, improved survival due to therapeutic advances, or demographic aging of the population, inferences about underlying causes differ substantially between PD, MS, and MNDs, with direct implications for health care planning and etiologic research.
- Open Access
- 4 November 2025
- Published by Springer Nature in Nature Aging
- Vol. 5 (11) , 2188-2196
Hospital-treated infectious diseases and the risk of epilepsy in older age
Infectious diseases are known to trigger acute seizures, but their long-term impact on epilepsy, especially in later life, is unclear. We conducted nested case–control studies of newly diagnosed epilepsy after age 50 in the UK Biobank (2,486 cases; 12,430 controls) and Swedish registers (56,266 cases; 281,330 controls), including a sibling comparison. Previous hospital-treated infections were associated with a persistently elevated epilepsy risk (for example, >10 years after infection: odds ratio (OR) 1.68, 95% confidence interval: 1.39–2.04 in UK Biobank; 1.46, 1.41–1.51 in Sweden). Associations were robust in sibling analyses and across infection types and sites. We further found that infections, together with a high cardiovascular genetic risk (OR 2.62, 2.22–3.08), a high cardiovascular risk score (OR 3.14, 2.68–3.68) or cardiovascular disease history (OR 4.77, 4.64–4.91), were associated with the highest epilepsy risk. Hospital-treated infections exert prolonged impact on epilepsy risk in older age, especially when in combination with cardiovascular risk factors.
- 4 November 2025
- Published by Springer Nature in Nature Aging
- Vol. 5 (11) , 2188-2196
Open AccessHospital-treated infectious diseases and the risk of epilepsy in older age
Infectious diseases are known to trigger acute seizures, but their long-term impact on epilepsy, especially in later life, is unclear. We conducted nested case–control studies of newly diagnosed epilepsy after age 50 in the UK Biobank (2,486 cases; 12,430 controls) and Swedish registers (56,266 cases; 281,330 controls), including a sibling comparison. Previous hospital-treated infections were associated with a persistently elevated epilepsy risk (for example, >10 years after infection: odds ratio (OR) 1.68, 95% confidence interval: 1.39–2.04 in UK Biobank; 1.46, 1.41–1.51 in Sweden). Associations were robust in sibling analyses and across infection types and sites. We further found that infections, together with a high cardiovascular genetic risk (OR 2.62, 2.22–3.08), a high cardiovascular risk score (OR 3.14, 2.68–3.68) or cardiovascular disease history (OR 4.77, 4.64–4.91), were associated with the highest epilepsy risk. Hospital-treated infections exert prolonged impact on epilepsy risk in older age, especially when in combination with cardiovascular risk factors.
- Open Access
- 28 August 2025
- Published by Karolinska Institutet
Infections in the risk and prognosis of multiple sclerosis and amyotrophic lateral sclerosis
Neurodegenerative diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are incurable, progressive, and heterogeneous. In MS, autoimmune T- and B-cell attacks against central-nervous-system myelin initiate focal demyelination, axonal injury, and gliosis, leading to clinically evident relapses that may evolve into slowly progressive disability even without further overt inflammation. ALS, by contrast, is characterized by selective degeneration of upper and lower motor neurons accompanied by cytoplasmic TDP-43 aggregation, microglial activation, oxidative stress, and metabolic dysregulation, typically culminating in progressive muscle weakness and respiratory failure within 3-5 years of onset. Although a dysregulated immune response and low-grade neuroinflammation are well-recognized components of both conditions, the contribution of infections to their initiation and course remains unclear. In this thesis, we investigated the bidirectional links between infections and MS and ALS, including post-diagnosis infection risk (Study I), impact of infections on MS progression under different treatments (Study II), role of hospital-treated infections in ALS risk and prognosis (Study III), and subclinical infections detected via a serological screening in ALS (Study IV).In Study I, we conducted both a community-based matched cohort and a twin study, using data from the UK Biobank and Swedish Twin Registry (UK Biobank: 2023 MS, 2200 Alzheimer's disease [AD], 3050 Parkinson's disease [PD] patients, and their individually matched healthy controls; Swedish Twin Registry: 230 twin pairs for the analysis of MS, 885 for AD, and 626 for PD). The aim was to investigate the incidence of serious infections following a diagnosis of MS, AD and PD, as well as the contribution of post-diagnostic infections on mortality after diagnosis of these conditions. Patients with MS, AD or PD exhibited significantly higher rates of hospital-treated infections after diagnosis compared to their matched healthy controls. Notably, an elevation in infection risk was already evident during the years preceding the diagnosis of these conditions, suggesting that immune alterations or preclinical disease processes may contribute to this early vulnerability. Causal mediation analysis indicated that infections experienced after diagnosis explained only a modest portion of the excess mortality risk associated with these diseases. In other words, while individuals with MS (and AD and PD) are more susceptible to infections, these infections only partially mediate the observed increase in mortality.In Study II, we conducted a nationwide registry-based cohort study in Sweden to examine infection risk and disability worsening in MS patients receiving different disease-modifying therapies. This study included over 16,000 MS treatment episodes, comprising 8,759 with the B-cell-depleting antibody rituximab and 7,561 with injectable interferon-ß or glatiramer acetate (IFN/GA). Rituximab-treated patients had approximately double the risk of hospital-treated infections compared to those treated with IFN/GA. Hospital-treated infections were significantly associated with disability worsening, measured as an increase in the Expanded Disability Status Scale scores; this association was most pronounced in progressive MS and in patients treated with IFN/GA. Among patients with relapsing-remitting MS treated with IFN/GA, an inpatient-treated infection was associated with greater subsequent disability progression after adjustment for relapses and MRI activity, whereas no such association was observed in patients treated with rituximab. These findings highlight a trade-off between infection risk and disease control, namely that, to optimize long-term outcomes, clinicians must balance the risk of infection against the benefit of preventing disease progression. Highly effective therapies such as rituximab increase susceptibility to infections but offer superior protection against the accumulation of disability in MS.In Study III, we conducted a nationwide nested case-control study using data from the Swedish Motor Neuron Disease Quality Registry to assess the role of infections in ALS. We identified all individuals newly diagnosed with ALS in Sweden between 2015 and 2023 and matched each case to three control groups: population controls and unaffected full siblings and spouses of ALS patients, thereby accounting for potential confounding by shared genetic and environmental factors between family members. The analysis showed that individuals who developed ALS were more likely to have a history of hospital-treated infections prior to diagnosis than controls, including population, sibling, and spouse controls. This finding suggests that previous serious infections are associated with an elevated risk of ALS, independent of familial background. Moreover, ALS patients with an experience of pre-diagnostic infections tended to present more frequently bulbar onset, lower functional status, and higher levels of anxiety and depressive symptoms at diagnosis. Following ALS diagnosis, the occurrence of a hospital-treated infection was associated with a higher mortality risk in ALS patients, whereas pre-diagnostic infections were not.In Study IV, we used a multiplex serological screening to identify infectious exposures linked to ALS. Within the ALSrisc Study (Biomarkers and Risk Factors for Amyotrophic Lateral Sclerosis), we analyzed blood samples from 500 incident ALS patients and three control groups (105 sibling controls, 170 spouse controls, and 106 mimic controls with other neurological disorders) for antibodies to a broad panel of common pathogens. A higher overall pathogen burden, defined as the total number of seropositive pathogens, was associated with an increased ALS risk. Seropositivity of specific pathogens, particularly Helicobacter pylori and Chlamydia trachomatis, showed the strongest association with case status;...
- 28 August 2025
- Published by Karolinska Institutet
Open AccessInfections in the risk and prognosis of multiple sclerosis and amyotrophic lateral sclerosis
Neurodegenerative diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are incurable, progressive, and heterogeneous. In MS, autoimmune T- and B-cell attacks against central-nervous-system myelin initiate focal demyelination, axonal injury, and gliosis, leading to clinically evident relapses that may evolve into slowly progressive disability even without further overt inflammation. ALS, by contrast, is characterized by selective degeneration of upper and lower motor neurons accompanied by cytoplasmic TDP-43 aggregation, microglial activation, oxidative stress, and metabolic dysregulation, typically culminating in progressive muscle weakness and respiratory failure within 3-5 years of onset. Although a dysregulated immune response and low-grade neuroinflammation are well-recognized components of both conditions, the contribution of infections to their initiation and course remains unclear. In this thesis, we investigated the bidirectional links between infections and MS and ALS, including post-diagnosis infection risk (Study I), impact of infections on MS progression under different treatments (Study II), role of hospital-treated infections in ALS risk and prognosis (Study III), and subclinical infections detected via a serological screening in ALS (Study IV).In Study I, we conducted both a community-based matched cohort and a twin study, using data from the UK Biobank and Swedish Twin Registry (UK Biobank: 2023 MS, 2200 Alzheimer's disease [AD], 3050 Parkinson's disease [PD] patients, and their individually matched healthy controls; Swedish Twin Registry: 230 twin pairs for the analysis of MS, 885 for AD, and 626 for PD). The aim was to investigate the incidence of serious infections following a diagnosis of MS, AD and PD, as well as the contribution of post-diagnostic infections on mortality after diagnosis of these conditions. Patients with MS, AD or PD exhibited significantly higher rates of hospital-treated infections after diagnosis compared to their matched healthy controls. Notably, an elevation in infection risk was already evident during the years preceding the diagnosis of these conditions, suggesting that immune alterations or preclinical disease processes may contribute to this early vulnerability. Causal mediation analysis indicated that infections experienced after diagnosis explained only a modest portion of the excess mortality risk associated with these diseases. In other words, while individuals with MS (and AD and PD) are more susceptible to infections, these infections only partially mediate the observed increase in mortality.In Study II, we conducted a nationwide registry-based cohort study in Sweden to examine infection risk and disability worsening in MS patients receiving different disease-modifying therapies. This study included over 16,000 MS treatment episodes, comprising 8,759 with the B-cell-depleting antibody rituximab and 7,561 with injectable interferon-ß or glatiramer acetate (IFN/GA). Rituximab-treated patients had approximately double the risk of hospital-treated infections compared to those treated with IFN/GA. Hospital-treated infections were significantly associated with disability worsening, measured as an increase in the Expanded Disability Status Scale scores; this association was most pronounced in progressive MS and in patients treated with IFN/GA. Among patients with relapsing-remitting MS treated with IFN/GA, an inpatient-treated infection was associated with greater subsequent disability progression after adjustment for relapses and MRI activity, whereas no such association was observed in patients treated with rituximab. These findings highlight a trade-off between infection risk and disease control, namely that, to optimize long-term outcomes, clinicians must balance the risk of infection against the benefit of preventing disease progression. Highly effective therapies such as rituximab increase susceptibility to infections but offer superior protection against the accumulation of disability in MS.In Study III, we conducted a nationwide nested case-control study using data from the Swedish Motor Neuron Disease Quality Registry to assess the role of infections in ALS. We identified all individuals newly diagnosed with ALS in Sweden between 2015 and 2023 and matched each case to three control groups: population controls and unaffected full siblings and spouses of ALS patients, thereby accounting for potential confounding by shared genetic and environmental factors between family members. The analysis showed that individuals who developed ALS were more likely to have a history of hospital-treated infections prior to diagnosis than controls, including population, sibling, and spouse controls. This finding suggests that previous serious infections are associated with an elevated risk of ALS, independent of familial background. Moreover, ALS patients with an experience of pre-diagnostic infections tended to present more frequently bulbar onset, lower functional status, and higher levels of anxiety and depressive symptoms at diagnosis. Following ALS diagnosis, the occurrence of a hospital-treated infection was associated with a higher mortality risk in ALS patients, whereas pre-diagnostic infections were not.In Study IV, we used a multiplex serological screening to identify infectious exposures linked to ALS. Within the ALSrisc Study (Biomarkers and Risk Factors for Amyotrophic Lateral Sclerosis), we analyzed blood samples from 500 incident ALS patients and three control groups (105 sibling controls, 170 spouse controls, and 106 mimic controls with other neurological disorders) for antibodies to a broad panel of common pathogens. A higher overall pathogen burden, defined as the total number of seropositive pathogens, was associated with an increased ALS risk. Seropositivity of specific pathogens, particularly Helicobacter pylori and Chlamydia trachomatis, showed the strongest association with case status;...
- Open Access
- 28 August 2025
- Published by Karolinska Institutet
Infections in the risk and prognosis of multiple sclerosis and amyotrophic lateral sclerosis
Neurodegenerative diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are incurable, progressive, and heterogeneous. In MS, autoimmune T- and B-cell attacks against central-nervous-system myelin initiate focal demyelination, axonal injury, and gliosis, leading to clinically evident relapses that may evolve into slowly progressive disability even without further overt inflammation. ALS, by contrast, is characterized by selective degeneration of upper and lower motor neurons accompanied by cytoplasmic TDP-43 aggregation, microglial activation, oxidative stress, and metabolic dysregulation, typically culminating in progressive muscle weakness and respiratory failure within 3-5 years of onset. Although a dysregulated immune response and low-grade neuroinflammation are well-recognized components of both conditions, the contribution of infections to their initiation and course remains unclear. In this thesis, we investigated the bidirectional links between infections and MS and ALS, including post-diagnosis infection risk (Study I), impact of infections on MS progression under different treatments (Study II), role of hospital-treated infections in ALS risk and prognosis (Study III), and subclinical infections detected via a serological screening in ALS (Study IV).In Study I, we conducted both a community-based matched cohort and a twin study, using data from the UK Biobank and Swedish Twin Registry (UK Biobank: 2023 MS, 2200 Alzheimer's disease [AD], 3050 Parkinson's disease [PD] patients, and their individually matched healthy controls; Swedish Twin Registry: 230 twin pairs for the analysis of MS, 885 for AD, and 626 for PD). The aim was to investigate the incidence of serious infections following a diagnosis of MS, AD and PD, as well as the contribution of post-diagnostic infections on mortality after diagnosis of these conditions. Patients with MS, AD or PD exhibited significantly higher rates of hospital-treated infections after diagnosis compared to their matched healthy controls. Notably, an elevation in infection risk was already evident during the years preceding the diagnosis of these conditions, suggesting that immune alterations or preclinical disease processes may contribute to this early vulnerability. Causal mediation analysis indicated that infections experienced after diagnosis explained only a modest portion of the excess mortality risk associated with these diseases. In other words, while individuals with MS (and AD and PD) are more susceptible to infections, these infections only partially mediate the observed increase in mortality.In Study II, we conducted a nationwide registry-based cohort study in Sweden to examine infection risk and disability worsening in MS patients receiving different disease-modifying therapies. This study included over 16,000 MS treatment episodes, comprising 8,759 with the B-cell-depleting antibody rituximab and 7,561 with injectable interferon-ß or glatiramer acetate (IFN/GA). Rituximab-treated patients had approximately double the risk of hospital-treated infections compared to those treated with IFN/GA. Hospital-treated infections were significantly associated with disability worsening, measured as an increase in the Expanded Disability Status Scale scores; this association was most pronounced in progressive MS and in patients treated with IFN/GA. Among patients with relapsing-remitting MS treated with IFN/GA, an inpatient-treated infection was associated with greater subsequent disability progression after adjustment for relapses and MRI activity, whereas no such association was observed in patients treated with rituximab. These findings highlight a trade-off between infection risk and disease control, namely that, to optimize long-term outcomes, clinicians must balance the risk of infection against the benefit of preventing disease progression. Highly effective therapies such as rituximab increase susceptibility to infections but offer superior protection against the accumulation of disability in MS.In Study III, we conducted a nationwide nested case-control study using data from the Swedish Motor Neuron Disease Quality Registry to assess the role of infections in ALS. We identified all individuals newly diagnosed with ALS in Sweden between 2015 and 2023 and matched each case to three control groups: population controls and unaffected full siblings and spouses of ALS patients, thereby accounting for potential confounding by shared genetic and environmental factors between family members. The analysis showed that individuals who developed ALS were more likely to have a history of hospital-treated infections prior to diagnosis than controls, including population, sibling, and spouse controls. This finding suggests that previous serious infections are associated with an elevated risk of ALS, independent of familial background. Moreover, ALS patients with an experience of pre-diagnostic infections tended to present more frequently bulbar onset, lower functional status, and higher levels of anxiety and depressive symptoms at diagnosis. Following ALS diagnosis, the occurrence of a hospital-treated infection was associated with a higher mortality risk in ALS patients, whereas pre-diagnostic infections were not.In Study IV, we used a multiplex serological screening to identify infectious exposures linked to ALS. Within the ALSrisc Study (Biomarkers and Risk Factors for Amyotrophic Lateral Sclerosis), we analyzed blood samples from 500 incident ALS patients and three control groups (105 sibling controls, 170 spouse controls, and 106 mimic controls with other neurological disorders) for antibodies to a broad panel of common pathogens. A higher overall pathogen burden, defined as the total number of seropositive pathogens, was associated with an increased ALS risk. Seropositivity of specific pathogens, particularly Helicobacter pylori and Chlamydia trachomatis, showed the strongest association with case status;...
- 28 August 2025
- Published by Karolinska Institutet
Open AccessInfections in the risk and prognosis of multiple sclerosis and amyotrophic lateral sclerosis
Neurodegenerative diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are incurable, progressive, and heterogeneous. In MS, autoimmune T- and B-cell attacks against central-nervous-system myelin initiate focal demyelination, axonal injury, and gliosis, leading to clinically evident relapses that may evolve into slowly progressive disability even without further overt inflammation. ALS, by contrast, is characterized by selective degeneration of upper and lower motor neurons accompanied by cytoplasmic TDP-43 aggregation, microglial activation, oxidative stress, and metabolic dysregulation, typically culminating in progressive muscle weakness and respiratory failure within 3-5 years of onset. Although a dysregulated immune response and low-grade neuroinflammation are well-recognized components of both conditions, the contribution of infections to their initiation and course remains unclear. In this thesis, we investigated the bidirectional links between infections and MS and ALS, including post-diagnosis infection risk (Study I), impact of infections on MS progression under different treatments (Study II), role of hospital-treated infections in ALS risk and prognosis (Study III), and subclinical infections detected via a serological screening in ALS (Study IV).In Study I, we conducted both a community-based matched cohort and a twin study, using data from the UK Biobank and Swedish Twin Registry (UK Biobank: 2023 MS, 2200 Alzheimer's disease [AD], 3050 Parkinson's disease [PD] patients, and their individually matched healthy controls; Swedish Twin Registry: 230 twin pairs for the analysis of MS, 885 for AD, and 626 for PD). The aim was to investigate the incidence of serious infections following a diagnosis of MS, AD and PD, as well as the contribution of post-diagnostic infections on mortality after diagnosis of these conditions. Patients with MS, AD or PD exhibited significantly higher rates of hospital-treated infections after diagnosis compared to their matched healthy controls. Notably, an elevation in infection risk was already evident during the years preceding the diagnosis of these conditions, suggesting that immune alterations or preclinical disease processes may contribute to this early vulnerability. Causal mediation analysis indicated that infections experienced after diagnosis explained only a modest portion of the excess mortality risk associated with these diseases. In other words, while individuals with MS (and AD and PD) are more susceptible to infections, these infections only partially mediate the observed increase in mortality.In Study II, we conducted a nationwide registry-based cohort study in Sweden to examine infection risk and disability worsening in MS patients receiving different disease-modifying therapies. This study included over 16,000 MS treatment episodes, comprising 8,759 with the B-cell-depleting antibody rituximab and 7,561 with injectable interferon-ß or glatiramer acetate (IFN/GA). Rituximab-treated patients had approximately double the risk of hospital-treated infections compared to those treated with IFN/GA. Hospital-treated infections were significantly associated with disability worsening, measured as an increase in the Expanded Disability Status Scale scores; this association was most pronounced in progressive MS and in patients treated with IFN/GA. Among patients with relapsing-remitting MS treated with IFN/GA, an inpatient-treated infection was associated with greater subsequent disability progression after adjustment for relapses and MRI activity, whereas no such association was observed in patients treated with rituximab. These findings highlight a trade-off between infection risk and disease control, namely that, to optimize long-term outcomes, clinicians must balance the risk of infection against the benefit of preventing disease progression. Highly effective therapies such as rituximab increase susceptibility to infections but offer superior protection against the accumulation of disability in MS.In Study III, we conducted a nationwide nested case-control study using data from the Swedish Motor Neuron Disease Quality Registry to assess the role of infections in ALS. We identified all individuals newly diagnosed with ALS in Sweden between 2015 and 2023 and matched each case to three control groups: population controls and unaffected full siblings and spouses of ALS patients, thereby accounting for potential confounding by shared genetic and environmental factors between family members. The analysis showed that individuals who developed ALS were more likely to have a history of hospital-treated infections prior to diagnosis than controls, including population, sibling, and spouse controls. This finding suggests that previous serious infections are associated with an elevated risk of ALS, independent of familial background. Moreover, ALS patients with an experience of pre-diagnostic infections tended to present more frequently bulbar onset, lower functional status, and higher levels of anxiety and depressive symptoms at diagnosis. Following ALS diagnosis, the occurrence of a hospital-treated infection was associated with a higher mortality risk in ALS patients, whereas pre-diagnostic infections were not.In Study IV, we used a multiplex serological screening to identify infectious exposures linked to ALS. Within the ALSrisc Study (Biomarkers and Risk Factors for Amyotrophic Lateral Sclerosis), we analyzed blood samples from 500 incident ALS patients and three control groups (105 sibling controls, 170 spouse controls, and 106 mimic controls with other neurological disorders) for antibodies to a broad panel of common pathogens. A higher overall pathogen burden, defined as the total number of seropositive pathogens, was associated with an increased ALS risk. Seropositivity of specific pathogens, particularly Helicobacter pylori and Chlamydia trachomatis, showed the strongest association with case status;...
- Open Access
- 5 August 2025
- Published by Wiley in Journal of Internal Medicine
- Vol. 298 (4) , 349-360
Hospital‐treated infections and the risk and prognosis of amyotrophic lateral sclerosis: A population‐based study
Background: Infection has been suspected as a risk factor for amyotrophic lateral sclerosis (ALS). However, previous research has focused on specific pathogens and rarely examined the influence of infection on disease progression. Objectives: To assess whether hospital‐treated infections correlate with the risk and prognosis of ALS. Methods: Using data from the Swedish Motor Neuron Disease Quality Registry, we conducted three nested case‐control studies, including 1159 individuals diagnosed with ALS during 2015–2023 and 5795 age‐ and sex‐matched population controls, 1558 full‐sibling controls, and 680 spouse controls, respectively. We used conditional logistic regression to estimate the association of hospital‐treated infections with subsequent risk of ALS and Cox model to assess the association of pre‐ or post‐diagnostic infections with mortality after an ALS diagnosis. Results: Hospital‐treated infections before diagnosis were associated with an increased risk of ALS in the population comparison (odds ratio [OR] 1.31; 95% confidence interval [CI] 1.15–1.49). A similar association was noted after excluding infections within 3‐, 5‐, or 10‐years preceding ALS diagnosis and was confirmed in sibling and spouse comparisons, although results were not always statistically significant. Patients with a hospital‐treated infection before diagnosis were more likely to present with bulbar symptoms, poorer functional status, and higher prevalence of anxiety and depressive symptoms at diagnosis than others. Pre‐diagnostic infections were not associated with mortality, whereas post‐diagnostic infections were associated with increased mortality (hazard ratio [HR] 1.89; 95%CI 1.59–2.24) among ALS patients. Conclusion: Hospital‐treated infections are associated with an increased risk of ALS and may modify its clinical presentation at diagnosis. Post‐diagnostic infections are associated with poor survival in ALS.
- 5 August 2025
- Published by Wiley in Journal of Internal Medicine
- Vol. 298 (4) , 349-360
Open AccessHospital‐treated infections and the risk and prognosis of amyotrophic lateral sclerosis: A population‐based study
Background: Infection has been suspected as a risk factor for amyotrophic lateral sclerosis (ALS). However, previous research has focused on specific pathogens and rarely examined the influence of infection on disease progression. Objectives: To assess whether hospital‐treated infections correlate with the risk and prognosis of ALS. Methods: Using data from the Swedish Motor Neuron Disease Quality Registry, we conducted three nested case‐control studies, including 1159 individuals diagnosed with ALS during 2015–2023 and 5795 age‐ and sex‐matched population controls, 1558 full‐sibling controls, and 680 spouse controls, respectively. We used conditional logistic regression to estimate the association of hospital‐treated infections with subsequent risk of ALS and Cox model to assess the association of pre‐ or post‐diagnostic infections with mortality after an ALS diagnosis. Results: Hospital‐treated infections before diagnosis were associated with an increased risk of ALS in the population comparison (odds ratio [OR] 1.31; 95% confidence interval [CI] 1.15–1.49). A similar association was noted after excluding infections within 3‐, 5‐, or 10‐years preceding ALS diagnosis and was confirmed in sibling and spouse comparisons, although results were not always statistically significant. Patients with a hospital‐treated infection before diagnosis were more likely to present with bulbar symptoms, poorer functional status, and higher prevalence of anxiety and depressive symptoms at diagnosis than others. Pre‐diagnostic infections were not associated with mortality, whereas post‐diagnostic infections were associated with increased mortality (hazard ratio [HR] 1.89; 95%CI 1.59–2.24) among ALS patients. Conclusion: Hospital‐treated infections are associated with an increased risk of ALS and may modify its clinical presentation at diagnosis. Post‐diagnostic infections are associated with poor survival in ALS.
- Open Access
- 12 December 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (1) , 1-11
Exploring clinical chemistry markers in amyotrophic lateral sclerosis: insights into survival and disease trajectories
Objective: Commonly measured clinical chemistry markers might be indicative of survival and disease progression in amyotrophic lateral sclerosis (ALS). Methods: In a cohort study of 270 ALS patients diagnosed from April 2014 to May 2021 in Stockholm, Sweden, we examined the link between 29 clinical chemistry markers at diagnosis and mortality risk at 6 months, 1 year, and 3 years after diagnosis. Summary variables from exploratory factor analysis (EFA) assessed the markers’ collective impact on survival. We integrated ALS functional rating scale-revised (ALSFRS-R) scores with survival data using a joint latent class model to identify patterns of functional decline. Multinomial logistic regression determined how the EFA-derived factors predicted the decline trajectories post-diagnosis. Results: Higher levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and albumin at diagnosis were linked to lower mortality in ALS patients, while increased neurofilament light chain (NfL), leukocyte count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and carbon dioxide (CO2) levels indicated higher mortality. The ‘Red blood cell profile’ factor, derived from EFA, emerged as a significant predictor of survival, independent of other prognostic indicators. The joint latent class model identified three distinct patient groups based on functional decline, with ‘Red blood cell profile’ suggesting a lower likelihood of being in the groups with slower progression. Conclusion: Clinical chemistry markers, including NfL, lipids, albumin, leukocyte count, MCV, MCH, CO2, and the ‘Red blood cell profile,’ were associated with ALS survival. As these markers represent broader bodily functions, integrating them in ALS patient care could improve disease management.
- 12 December 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (1) , 1-11
Open AccessExploring clinical chemistry markers in amyotrophic lateral sclerosis: insights into survival and disease trajectories
Objective: Commonly measured clinical chemistry markers might be indicative of survival and disease progression in amyotrophic lateral sclerosis (ALS). Methods: In a cohort study of 270 ALS patients diagnosed from April 2014 to May 2021 in Stockholm, Sweden, we examined the link between 29 clinical chemistry markers at diagnosis and mortality risk at 6 months, 1 year, and 3 years after diagnosis. Summary variables from exploratory factor analysis (EFA) assessed the markers’ collective impact on survival. We integrated ALS functional rating scale-revised (ALSFRS-R) scores with survival data using a joint latent class model to identify patterns of functional decline. Multinomial logistic regression determined how the EFA-derived factors predicted the decline trajectories post-diagnosis. Results: Higher levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and albumin at diagnosis were linked to lower mortality in ALS patients, while increased neurofilament light chain (NfL), leukocyte count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and carbon dioxide (CO2) levels indicated higher mortality. The ‘Red blood cell profile’ factor, derived from EFA, emerged as a significant predictor of survival, independent of other prognostic indicators. The joint latent class model identified three distinct patient groups based on functional decline, with ‘Red blood cell profile’ suggesting a lower likelihood of being in the groups with slower progression. Conclusion: Clinical chemistry markers, including NfL, lipids, albumin, leukocyte count, MCV, MCH, CO2, and the ‘Red blood cell profile,’ were associated with ALS survival. As these markers represent broader bodily functions, integrating them in ALS patient care could improve disease management.
- Open Access
- 10 December 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 49, 101173
Association between cardiometabolic diseases and the risk and progression of motor neuron diseases in Sweden: a population-based case–control study
- 10 December 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 49, 101173
Open AccessAssociation between cardiometabolic diseases and the risk and progression of motor neuron diseases in Sweden: a population-based case–control study
- Open Access
- 22 November 2024
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 42, 100907
Immune cells and the trajectories of depression, anxiety, and cognitive function among people with amyotrophic lateral sclerosis
- 22 November 2024
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 42, 100907
Open AccessImmune cells and the trajectories of depression, anxiety, and cognitive function among people with amyotrophic lateral sclerosis
- Open Access
- 10 July 2024
- Published by Wiley in Annals of Neurology
- Vol. 96 (4) , 694-703
Hospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis
Objective: To investigate the association between infections and disability worsening in people with multiple sclerosis (MS) treated with either B‐cell depleting therapy (rituximab) or interferon‐beta/glatiramer acetate (IFN/GA).Methods: This cohort study spanned from 2000 to 2021, using data from the Swedish MS Registry linked to national health care registries, comprising 8,759 rituximab and 7,561 IFN/GA treatment episodes. The risk of hospital‐treated infection was estimated using multivariable Cox models. The association between infections and increase in Expanded Disability Status Scale (EDSS) scores was assessed using a doubly robust generalized estimating equations model. Additionally, a piece‐wise exponential model analyzed events of increased disability beyond defined cut‐off values, controlling for relapses, and MRI activity.Results: Compared with IFN/GA, rituximab displayed increased risk of both inpatient‐ and outpatient‐treated infections (hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.50–2.90 and HR, 1.37; 95% CI, 1.13–1.67, respectively). An inpatient‐treated infection was associated with a 0.19‐unit increase in EDSS (95% CI, 0.12–0.26). Degree of worsening was greatest for progressive MS, and under IFN/GA treatment, which unlike rituximab, was more commonly associated with MRI activity. After controlling for relapses and MRI activity, inpatient‐treated infections were associated with disability worsening in people with relapsing–remitting MS treated with IFN/GA (HR, 2.01; 95% CI, 1.59–2.53), but not in those treated with rituximab.Interpretation: Compared to IFN/GA, rituximab doubled the infection risk, but reduced the risk of subsequent disability worsening. Further, the risk of worsening after hospital‐treated infection was greater with progressive MS than with relapsing–remitting MS. Infection risk should be considered to improve long term outcomes. ANN NEUROL 2024;96:694–703
- 10 July 2024
- Published by Wiley in Annals of Neurology
- Vol. 96 (4) , 694-703
Open AccessHospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis
Objective: To investigate the association between infections and disability worsening in people with multiple sclerosis (MS) treated with either B‐cell depleting therapy (rituximab) or interferon‐beta/glatiramer acetate (IFN/GA).Methods: This cohort study spanned from 2000 to 2021, using data from the Swedish MS Registry linked to national health care registries, comprising 8,759 rituximab and 7,561 IFN/GA treatment episodes. The risk of hospital‐treated infection was estimated using multivariable Cox models. The association between infections and increase in Expanded Disability Status Scale (EDSS) scores was assessed using a doubly robust generalized estimating equations model. Additionally, a piece‐wise exponential model analyzed events of increased disability beyond defined cut‐off values, controlling for relapses, and MRI activity.Results: Compared with IFN/GA, rituximab displayed increased risk of both inpatient‐ and outpatient‐treated infections (hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.50–2.90 and HR, 1.37; 95% CI, 1.13–1.67, respectively). An inpatient‐treated infection was associated with a 0.19‐unit increase in EDSS (95% CI, 0.12–0.26). Degree of worsening was greatest for progressive MS, and under IFN/GA treatment, which unlike rituximab, was more commonly associated with MRI activity. After controlling for relapses and MRI activity, inpatient‐treated infections were associated with disability worsening in people with relapsing–remitting MS treated with IFN/GA (HR, 2.01; 95% CI, 1.59–2.53), but not in those treated with rituximab.Interpretation: Compared to IFN/GA, rituximab doubled the infection risk, but reduced the risk of subsequent disability worsening. Further, the risk of worsening after hospital‐treated infection was greater with progressive MS than with relapsing–remitting MS. Infection risk should be considered to improve long term outcomes. ANN NEUROL 2024;96:694–703
- Open Access
- 2 March 2023
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 5 (2) , fcad065
Infections among individuals with multiple sclerosis, Alzheimer’s disease and Parkinson’s disease
A link between neurodegenerative diseases and infections has been previously reported. However, it is not clear to what extent such link is caused by confounding factors or to what extent it is intimately connected with the underlying conditions. Further, studies on the impact of infections on mortality risk following neurodegenerative diseases are rare. We analysed two data sets with different characteristics: (i) a community-based cohort from the UK Biobank with 2023 patients with multiple sclerosis, 2200 patients with Alzheimer’s disease, 3050 patients with Parkinson’s disease diagnosed before 1 March 2020 and 5 controls per case who were randomly selected and individually matched to the case; (ii) a Swedish Twin Registry cohort with 230 patients with multiple sclerosis, 885 patients with Alzheimer’s disease and 626 patients with Parkinson’s disease diagnosed before 31 December 2016 and their disease-free co-twins. The relative risk of infections after a diagnosis of neurodegenerative disease was estimated using stratified Cox models, with adjustment for differences in baseline characteristics. Causal mediation analyses of survival outcomes based on Cox models were performed to assess the impact of infections on mortality. Compared with matched controls or unaffected co-twins, we observed an elevated infection risk after diagnosis of neurodegenerative diseases, with a fully adjusted hazard ratio (95% confidence interval) of 2.45 (2.24–2.69) for multiple sclerosis, 5.06 (4.58–5.59) for Alzheimer’s disease and 3.72 (3.44–4.01) for Parkinson’s disease in the UK Biobank cohort, and 1.78 (1.21–2.62) for multiple sclerosis, 1.50 (1.19–1.88) for Alzheimer’s disease and 2.30 (1.79–2.95) for Parkinson’s disease in the twin cohort. Similar risk increases were observed when we analysed infections during the 5 years before diagnosis of the respective disease. Occurrence of infections after diagnosis had, however, relatively little impact on mortality, as mediation of infections on mortality (95% confidence interval) was estimated as 31.89% (26.83–37.11%) for multiple sclerosis, 13.38% (11.49–15.29%) for Alzheimer’s disease and 18.85% (16.95–20.97%) for Parkinson’s disease in the UK Biobank cohort, whereas it was 6.56% (−3.59 to 16.88%) for multiple sclerosis, −2.21% (−0.21 to 4.65%) for Parkinson’s disease and −3.89% (−7.27 to −0.51%) for Alzheimer’s disease in the twin cohort. Individuals with studied neurodegenerative diseases display an increased risk of infections independently of genetic and familial environment factors. A similar magnitude of risk increase is present prior to confirmed diagnosis, which may indicate a modulating effect of the studied neurological conditions on immune defences.
- 2 March 2023
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 5 (2) , fcad065
Open AccessInfections among individuals with multiple sclerosis, Alzheimer’s disease and Parkinson’s disease
A link between neurodegenerative diseases and infections has been previously reported. However, it is not clear to what extent such link is caused by confounding factors or to what extent it is intimately connected with the underlying conditions. Further, studies on the impact of infections on mortality risk following neurodegenerative diseases are rare. We analysed two data sets with different characteristics: (i) a community-based cohort from the UK Biobank with 2023 patients with multiple sclerosis, 2200 patients with Alzheimer’s disease, 3050 patients with Parkinson’s disease diagnosed before 1 March 2020 and 5 controls per case who were randomly selected and individually matched to the case; (ii) a Swedish Twin Registry cohort with 230 patients with multiple sclerosis, 885 patients with Alzheimer’s disease and 626 patients with Parkinson’s disease diagnosed before 31 December 2016 and their disease-free co-twins. The relative risk of infections after a diagnosis of neurodegenerative disease was estimated using stratified Cox models, with adjustment for differences in baseline characteristics. Causal mediation analyses of survival outcomes based on Cox models were performed to assess the impact of infections on mortality. Compared with matched controls or unaffected co-twins, we observed an elevated infection risk after diagnosis of neurodegenerative diseases, with a fully adjusted hazard ratio (95% confidence interval) of 2.45 (2.24–2.69) for multiple sclerosis, 5.06 (4.58–5.59) for Alzheimer’s disease and 3.72 (3.44–4.01) for Parkinson’s disease in the UK Biobank cohort, and 1.78 (1.21–2.62) for multiple sclerosis, 1.50 (1.19–1.88) for Alzheimer’s disease and 2.30 (1.79–2.95) for Parkinson’s disease in the twin cohort. Similar risk increases were observed when we analysed infections during the 5 years before diagnosis of the respective disease. Occurrence of infections after diagnosis had, however, relatively little impact on mortality, as mediation of infections on mortality (95% confidence interval) was estimated as 31.89% (26.83–37.11%) for multiple sclerosis, 13.38% (11.49–15.29%) for Alzheimer’s disease and 18.85% (16.95–20.97%) for Parkinson’s disease in the UK Biobank cohort, whereas it was 6.56% (−3.59 to 16.88%) for multiple sclerosis, −2.21% (−0.21 to 4.65%) for Parkinson’s disease and −3.89% (−7.27 to −0.51%) for Alzheimer’s disease in the twin cohort. Individuals with studied neurodegenerative diseases display an increased risk of infections independently of genetic and familial environment factors. A similar magnitude of risk increase is present prior to confirmed diagnosis, which may indicate a modulating effect of the studied neurological conditions on immune defences.